YaleNewHaven**Health** 

## **Smilow Cancer Hospital**

## **Grand Rounds**



Join us in person for lunch!

TUESDAY, December 6, 12:00pm 55 Park St., Smilow Auditorium | <u>Zoom</u> Access Hosted by the Melanoma Program

Epigenetic regulation of immune evasion and drug resistance in melanoma and beyond



## Qin Yan, PhD

Professor of Pathology; Co-Leader, Genomics, Genetics, & Epigenetics Research Program

**Needs:** The roles of epigenetic regulation in immune evasion and drug resistance by cancer cells, and the development of drugs to target epigenetic regulators. Highlight basic and translational research that led to the discovery of new roles of KDM5B histone demethylase in melanoma.

**Objectives:** Understand the importance of epigenetic contribution to cancer initiation and progression. Learn the roles of KDM5B histone demethylase in melanoma. Recognize new therapeutic avenues for cancer treatment.





There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for *1 AMA PRA Category 1 Credit(s)*<sup>M</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smillow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Yan- AZ - Research Support. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity